Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118370 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL30977677 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29366757 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29613402 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL12537019 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1486216 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29352409 | 1.00 | MDM4 (0.61) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29519824 | 0.95 | MDM4 (0.57) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL6742006 | 0.92 | MDM4 (0.55) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29451083 | 0.91 | CASP3 (0.59) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264952-A2 | NOVEL RNA THERAPEUTICS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4638745-A1 | NOVEL FAS RNAI THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638747-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Eli Lilly and Company (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250275975-A1 | Methods of Treating Neuropathies | ATHIRA PHARMA, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4544050-A2 | ATXN2 RNA INTERFERENCE AGENTS | Eli Lilly and Company (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119768519-A | ATXN2 RNA interference reagent | 伊莱利利公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119630640-A | Process for the production of O-substituted serine derivatives | 中外制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| EP-4493692-A1 | SARM1 RNA INTERFERENCE AGENTS | Eli Lilly and Company (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-4482510-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | Athira Pharma, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024138111-A1 | NOVEL RNA THERAPEUTICS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024137729-A1 | NOVEL FAS RNAi THERAPEUTICS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4359529-A1 | NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF | Eli Lilly and Company (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117858948-A | Novel therapeutic agent delivery moieties and uses thereof | 伊莱利利公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023177972-A1 | SARM1 RNA INTERFERENCE AGENTS | ELI LILLY AND COMPANY (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023163971-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | ATHIRA PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-114948860-B | Supermolecule hydrogel nano material, gel factor, preparation method and application thereof | 东南大学 | 2023-04-28 | — | — | CN | disclosed |
| WO-2022271806-A1 | NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275975-A1 | Methods of Treating Neuropathies | NGF, HGF, HDGF | MDM4 2464/4885TP53 1714/4885CASP3 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.